Bin1: A Novel Tumor Suppressor Protein
George C. Prendergast and Daitoku Sakamuro
Immunohistochemical analysis of thirty frozen cases of prostate cancer indicated that presumptive altered forms of the protein specifically accumulate to high levels in cells that are malignant, but not benign or atrophic. Prostatic intraepithelial neoplasia is also specifically stained. Thus, Bin1 may offer a needed histochemical marker for differential diagnosis and possibly prognosis of prostate cancer.
Bin1 is a new target for development of novel therapeutics and diagnostics. Bin1 sequences may be useful for research, clinical diagnostics, or clinical therapeutics against cancer or other hyperproliferative diseases. Bin1 antibodies may be useful for research, diagnostic, or therapeutic applications, including staging and possible prognosis of prostate cancer. Additionally, Bin1-derived peptides might be useful as a starting point for drug design.
Wistar is seeking sponsored research and/or a licensee to develop therapeutic and diagnostic applications of Bin1. Additionally, Wistar is seeking non-exclusive licenses for antibodies to Bin1 for use as research and/or diagnostic reagents.